| Literature DB >> 22797177 |
Nannan Lu1, Qin Liu, Rutian Li, Li Xie, Jie Shen, Wenxian Guan, Xiaoping Qian, Lixia Yu, Yitao Ding, Xiqun Jiang, Baorui Liu.
Abstract
Novel pemetrexed-loaded gelatinase-responsive nanoparticles were prepared as a targeted delivery system to determine its potential for clinical therapy of malignant melanoma. The pemetrexed-loaded poly(ethylene glycol)(PEG)-peptide-poly(ε-caprolactone) (PCL) nanoparticles included a gelatinase-cleavage peptide and a PEG-PCL-based structure. The pemetrexed-loaded PEG-peptide-PCL nanoparticles have shown the best antimetastatic effect in experimental lung metastasis models. The expressions of CD133 and thymidylate synthetase of metastatic tumors were also evaluated in our studies. Our results showed that pemetrexed-loaded gelatinase-responsive nanoparticles may represent a potent drug delivery system for inhibiting pulmonary metastasis and our preclinical results can provide new avenues for clinical therapy of malignant melanoma.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22797177 DOI: 10.1097/CAD.0b013e328356dc11
Source DB: PubMed Journal: Anticancer Drugs ISSN: 0959-4973 Impact factor: 2.248